ArticleStem cell research & therapy2020
Cellular therapy of corneal epithelial defect by adipose mesenchymal stem cell-derived epithelial progenitors.
Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 69 citations in OpenAlex.
- Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects.Translational vision science & technology · 2022Trial
- Stem Cell Therapy: Past, Present, and Future Aspects.Biomedicines · 2026Review
- Morphological characteristics of corneal stromal stem cells and their age-related decline.Scientific reports · 2026Article
- A novel single-cell level evaluation method for corneal endothelial cell function.NPJ digital medicine · 2025Article
- Current and Emerging Approaches in the Management of Severe Ocular Surface Disease.Medicina (Kaunas, Lithuania) · 2025Review
- TLR3-overexpressing umbilical cord mesenchymal stromal cells suppress immune responses to attenuate high-risk corneal transplantation rejection.Stem cell research & therapy · 2025Article
- The cell-fate decision of dental follicle stem cells (DFSCs) with porcine corneal extracellular matrix (ECM).Journal of dental sciences · 2025Article
- Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025Review
- Progress in Transdifferentiation of Autologous Alternative Cell Sources into Corneal Epithelial Cells.Stem cell reviews and reports · 2025Review
- Epithelial differentiation of gingival mesenchymal stem cells enhances re-epithelialization for full-thickness cutaneous wound healing.Stem cell research & therapy · 2024Article
- Differentiation of Human Mesenchymal Stem Cells into Corneal Epithelial Cells: Current Progress.Current issues in molecular biology · 2024Review
- Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold.Regenerative medicine · 2024Article
- Developing fibrin-based biomaterials/scaffolds in tissue engineering.Bioactive materials · 2024Review
- Characterization of 3D Organotypic Culture of Mouse Adipose-Derived Stem Cells.International journal of molecular sciences · 2024Article
- Replace or Regenerate? Diverse Approaches to Biomaterials for Treating Corneal Lesions.Biomimetics (Basel, Switzerland) · 2024Review
- Animal Models for Limbal Stem Cell Deficiency: A Critical Narrative Literature Review.Ophthalmology and therapy · 2024Review
- Unlocking the versatile potential: Adipose-derived mesenchymal stem cells in ocular surface reconstruction and oculoplastics.World journal of stem cells · 2024Review
- Advanced bioengineering strategies broaden the therapeutic landscape for corneal failure.Frontiers in bioengineering and biotechnology · 2024Review
- Corneal Reconstruction with EGFP-Labelled Limbal Mesenchymal Stem Cells in a Rabbit Model of Limbal Stem Cell Deficiency.International journal of molecular sciences · 2023Article
- Prolonged Inflammation and Infectious Changes in the Corneal Epithelium Are Associated with Persistent Epithelial Defect (PED).Pathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistent epithelial defects (PED), associated with limbal stem cell deficiency (LSCD), require ocular surface reconstruction with a stable corneal epithelium (CE). This study investigated CE reformation using human adipose mesenchymal stem cells (ADSC), which derived epithelial progenitors via mesenchymal-epithelial transition (MET).
methodsSTEMPRO human ADSC were cultured with specific inhibitors antagonizing glycogen synthase kinase-3 and transforming growth factor-β signaling, followed by culture under a defined progenitor cell targeted-epithelial differentiation condition to generate epithelial-like cells (MET-Epi), which were characterized for cell viability, mesenchymal, and epithelial phenotypes using immunofluorescence and flow cytometry. Tissue-engineered (TE) MET-Epi cells on fibrin gel were transplanted to corneal surface of the rat LSCD model caused by alkali injury. Epithelial healing, corneal edema, and haze grading, CE formation were assessed by fluorescein staining, slit lamp bio-microscopy, anterior segment optical coherence tomography, and immunohistochemistry.
resultsCD73
conclusionHuman ADSC-derived epithelial-like cells, via MET, recovered the CE from PED associated with LSCD. ADSC can be a viable adult stem cell source for potential autologous epithelial cell-based therapy for corneal surface disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.